# Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

> **NCT01701986** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 64 (actual)

## Conditions studied

- Hematopoietic Cell Transplantation Recipient
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Refractory T-Cell Non-Hodgkin Lymphoma

## Interventions

- **PROCEDURE:** Allogeneic Bone Marrow Transplantation
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **BIOLOGICAL:** Anti-Thymocyte Globulin
- **DRUG:** Busulfan
- **DRUG:** Clofarabine
- **DRUG:** Gemcitabine Hydrochloride
- **DRUG:** Mycophenolate Mofetil
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **OTHER:** Pharmacological Study
- **BIOLOGICAL:** Rituximab
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT01701986
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-25
- **Primary completion:** 2024-06-05
- **Final completion:** 2024-06-05
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01701986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01701986, "Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01701986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*